Stagg Brian, Stein Joshua D, Medeiros Felipe A, Cummins Mollie, Kawamoto Kensaku, Hess Rachel
Ophthalmology and Visual Sciences, University of Utah Health John A Moran Eye Center, Salt Lake City, Utah, USA.
Population Health Sciences, University of Utah Health, Salt Lake City, Utah, USA.
BMJ Open Ophthalmol. 2021 Jan 15;6(1):e000639. doi: 10.1136/bmjophth-2020-000639. eCollection 2021.
To study whether clinicians who treat glaucoma are interested in using clinical decision support (CDS) tools for glaucoma, what glaucoma clinical decisions they feel would benefit from CDS, and what characteristics of CDS design they feel would be important in glaucoma clinical practice.
Working with the American Glaucoma Society, the Utah Ophthalmology Society and the Utah Optometric Association, we identified a group of clinicians who care for patients with glaucoma. We asked these clinicians about interest in CDS, what glaucoma clinical decisions would benefit from CDS, and what characteristics of CDS tool design would be important in glaucoma clinical practice.
Of the 105 clinicians (31 optometrists, 10 general ophthalmologists and 64 glaucoma specialists), 93 (88.6%) were either 'definitely' or 'probably' interested in using CDS for glaucoma. There were no statistically significant differences in interest between clinical specialties (p=0.12), years in practice (p=0.85) or numbers of patients seen daily (p=0.99). Identifying progression of glaucoma was the clinical decision the largest number of clinicians felt would benefit from CDS (104/105, 99.1%). An easy to use interface was the CDS characteristic the largest number of clinicians felt would be 'very important' (93/105, 88.6%).
Of this group of clinicians who treat glaucoma, 88.6% were interested in using CDS for glaucoma and 99.1% felt that identification of glaucomatous progression could benefit from CDS. This level of interest supports future work to develop CDS for glaucoma.
研究治疗青光眼的临床医生是否有兴趣使用青光眼临床决策支持(CDS)工具,他们认为哪些青光眼临床决策将从CDS中受益,以及他们认为CDS设计的哪些特征在青光眼临床实践中很重要。
我们与美国青光眼协会、犹他州眼科学会和犹他州验光师协会合作,确定了一组诊治青光眼患者的临床医生。我们询问这些临床医生对CDS的兴趣、哪些青光眼临床决策将从CDS中受益,以及CDS工具设计的哪些特征在青光眼临床实践中很重要。
在105名临床医生(31名验光师、10名普通眼科医生和64名青光眼专科医生)中,93名(88.6%)“肯定”或“可能”有兴趣使用CDS来治疗青光眼。不同临床专科(p = 0.12)、从业年限(p = 0.85)或每日接诊患者数量(p = 0.99)之间在兴趣方面无统计学显著差异。确定青光眼进展是大多数临床医生认为将从CDS中受益的临床决策(104/105,99.1%)。易于使用的界面是大多数临床医生认为“非常重要”的CDS特征(93/105,88.6%)。
在这组治疗青光眼的临床医生中,88.6%有兴趣使用CDS来治疗青光眼,99.1%认为青光眼进展的识别可从CDS中受益。这种兴趣水平支持未来开展针对青光眼的CDS开发工作。